Oxford Vacmedix UK Limited
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. Oxford Vacmedix is looking for large pharmaceutical companies interested in co-developing the ROP technology, NHS hospitals to participate in clinical trials of the lead vaccines, and firms that can sequence tumour mutations against which it can design personalised vaccines (neoantigens). Oxford Vacmedix is looking for a large pharmaceutical firm to codevelop its ROP technology, a suitable CMO for GMP-level production for its preclinical/phase 1 vaccine trials in Europe.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Internationally (various countries)
- Year Founded:
- 2012
About us
Partnering outlook
The Company is also interested in collaborating with leading pharma companies that can provide checkpoint inhibitors suitable for combination with ROP vaccines.
Oxford Vacmedix is currently looking for Series B equity investment. Funds will be used to accelerate the development of the lead cancer vaccines, OVM-200 and OVM-100, and to finish development and to commercialise the novel diagnostic test for anti-microbial resistance.